Abstract
Successful treatment for diseases such as cancer and AIDS will likely involve particular combinations of drug therapy, immunotherapy, and gene therapy. Gene therapy is a novel approach currently under development for treatment of a variety of diseases (Anderson 1998). This novel therapy offers a fresh alternative, which endows a therapeutic effect by introduction of a particular gene into targeted cells. The effect of gene therapy in the host will depend, in part, on the efficiency of the vector system used to deliver the effector molecule. Numerous vector constructions have been used to deliver and express genes in human cells. Biological vectors for gene therapy are constructed from several viruses that include herpes simplex virus type 1, adenovirus, adenoassociated virus, and retroviruses (Kay et al. 2001; Robbins et al. 1998; Romano et al. 2000; Smith 1999; Wolfe et al. 1999; Wu and Ataai 2000). Among these vectors, retroviruses are most widely used as an efficient means for introducing foreign DNA into the cell genome. The life cycle of retroviruses involves stable integration of viral genetic material into the host genome; expression of viral genes is, in part, regulated by host cell factors (Coffin et al. 1997). These features of retroviruses make them useful for selected applications of gene transfer in animals and humans. Retroviral vectors are significant for basic biological investigations such as studies of cell lineage, mechanisms of carcinogenesis, and developmental and tissue-specific regulation of defined DNA sequences as well as clinical uses for gene therapy (Varmus 1988). Clinical applications of retroviral
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bock M, Heinkelein M, Lindemann D, Rethwilm A (1998) Cells expressing the human foamy virus (HFV) accessory Bet protein are resistant to productive HFV superinfection. Virology 250:194-204
Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M (1992) Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 89:6580-6584
Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Nail Acad Sci USA 90:8033-8037
Cain D, Erlwein O, Grigg A, Russell RA and McClure MO (2001) Palindromic sequence plays a critical role in human foamy virus dimerization. J Virol 75:3731-3739
Callahan ME, Switzer WM, Matthews AL, Roberts BD, Heneine W, Folks TM, Sandstrom PA (1999) Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene. J Virol 73:9619-9624
Campbell M, Renshaw-Gegg L, Renne R, Luciw PA (1994) Characterization of the internal promoter of simian foamy viruses. J Virol 68:4811-4820
Cavazzana-Calvo M, Hacein-Bey S, de-Saint-Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-72
Charneau P, Alizon M, Clavel F (1992) A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol 66:2814-2820
Civin C (2000) Gene therapy in clinical applications. Stem Cells 180:150-156
Clavel F, Orenstein JM (1990) A mutant of human immunodeficiency virus with re- duced RNA packaging and abnormal particle morphology. J Virol 64:5230-5234
Clever JL, Parslow TG (1997) Mutant human immunodeficiency virus type 1 gen- omes with defects in RNA dimerization or encapsidation. J Virol 71:3407-3414
Coffin JM, Hughes SH, Varmus HE, eds (1997) Retroviruses. Cold Spring Harbor Laboratory Press, New York
Eglitis MA, Anderson WF (1988) Retroviral vectors for introduction of genes into mammalian cells. BioTechniques 6:608-614
Enssle J, Fischer N, Moebes A, Mauer B, Smola U, Rethwilm A (1997) Carboxy-terminal cleavage of the human foamy virus gag precursor molecule is an essential step in the viral life cycle. J Virol 71:7312-7317
Erlwein O, Bieniasz PD, McClure MO (1998) Sequences in pol are required for transfer of human foamy virus-based vectors. J Virol 72:5510-5516
Erlwein O, Cain D, Fischer N, Rethwilm A, McClure MO (1997) Identification of sites that act together to direct dimerization of human foamy virus RNA in vitro. Virology 229:251-258
Fauci AS (1996) Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-534
Federico M (1999) Lentiviruses as gene delivery vectors. Curr Opin Biotechnol 10:448-453
Fischer N, Heinkelein M, Lindemann D, Enssle J, Baum C, Werder E, Zentgraf H, Muller JG, Rethwilm A (1998) Foamy virus particle formation. J Virol 72:16101615
Flügel RM (1991) Spumaviruses: a group of complex retroviruses. J AIDS 4:739-750
Flügel RM, Rethwilm A, Maurer B, Darai G (1987) Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes. EMBO J 6:2077-84
Gallay P, Stitt V, Mundy C, Oettinger M, Trono D (1996) Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 70:1027-1032
Giron ML, Rozain F, Debons-Guillemin MC, Canivet M, Perks J, Emanoil-Ravier R (1993) Human foamy virus polypeptides: identification of env and bel gene products. J Virol 67:3596-3600
Gunji Y, Ochiai T, Shimada H, Matsubara H (2000) Gene therapy for cancer. Surg Today 30:967-73
Hahn H, Gerald B, Brautigam S, Mergia A, Neumann-Haefelin D, Daniel MD, McClure MO, Rethwilm A (1994) Reactivity of primate sera to foamy virus Gag and Bet proteins. J Gen Virol 75:2635-2644
He F, Sun JD, Garrett ED, Cullen BR (1993) Functional organization of the Bel-1 transactivator of human foamy virus. J Virol 67:1896-1904
Heinkelein M, Schmidt M, Fischer N, Moebes A, Lindemann D, Enssle J, Rethwilm A (1998) Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol 72:6307-6314
Heinkelein M, Thurow J, Dressler M, Imrich H, Neumann-Haefelin D, McClure MO, Rethwilm A (2000a) Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging. J Virol 74:3141-3148
Heinkelein M, Pietschmann T, Jarmy G, Dressler M, Imrich H, Thurow J, Lindemann D, Bock M, Moebes A, Roy J, Herchenröder O and Rethwilm A (2000b) Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO J 19:3436-3445
Heinkelein M, Dressler M, Jarmy G, Rammling M, Imrich H, Thurow J, Lindemann D and Rethwilm A (2002a) Improved primate foamy virus vectors and packaging constructs. J Virol 76:3774-3783
Heinkelein M, Leurs C, Rammling M, Peters K, Hanenberg H and Rethwilm A (2002b) Pregenomic RNA is required for efficient incorporation of Pol polyprotein into foamy virus capsids. J Virol 76:(in press)
Heneine W, Switzer WM, Sandstrom P, Brown J, Vedapuri S, Schable CA, Khan AS, Lerche NW, Schweizer M, Neumann-Haefelin D, Chapman LE, Folks TM (1998) Identification of a human population infected with simian foamy viruses. Nat Med 4:403-407
Herchenröder O, Renne R, Loncar D, Cobb EK, Murthy KK, Schneider J, Mergia A, Luciw PA (1994) Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). Virology 201:187-199
Herchenröder O, Turek R, Neumann-Haefelin D, Rethwilm A, Schneider J (1995) Infectious proviral clones of chimpanzee foamy virus (SFVcpz) generated by long PCR reveal close functional relatedness to human foamy virus. Virology 214:685-689
Hildinger M, Abel KL, Ostertag W and Baum C (1999) Design of 5' untranslated se- quences in retroviral vectors developed for medical use. J Virol 73:4083-4089
Hill CL, Bieniasz PD, McClure MO (1999) Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 80:2003-2009
Hirata RK, Miller AD, Andrews RG, Russell DW (1996) Transduction of hematopoi- etic cells by foamy virus vectors. Blood 88:3654-3661
Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, Deist Fl, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D (1996) Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 3:179-83
Hooks JJ, Detrick-Hooks B (1981) Spumavirinae: foamy virus group infections. Comparative aspects and diagnosis. In: Kurstak E, Kurstak C (eds) Comparative Diagnosis of Viral Disease. Academic Press, New York
Josephson NC, Vassilopoulos G, Trobridge GD, Priestley GV, Wood BL, Papayannopoulou T, Russell DW (2002) Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 99:8295-8300
Kantoff PW, Freeman SM, Anderson WF (1988) Prospects for gene therapy for immunodeficiency diseases. Annu Rev Immunol 6:581-594
Kaplan AH, Swanstrom R (1991) Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Nad Acad Sci USA 88:4528-4532
Katz RA, Terry RW, Skalka AM (1986) A conserved cis-acting sequence in the 5' lead- er of avian sarcoma virus RNA is required for packaging. J Virol 59:163-167
Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Med 7:33-40
Keller A, Partin KM, Löchelt M, Bannert H, Flügel RM, Cullen BR (1991) Characterization of the transcriptional trans-activator of human foamy virus. J Virol 65:2589-2594
Kim HJ, Lee K, O'Rear JJ (1994) A short sequence upstream of the 5“ major splice site is important for encapsidation of HIV-1 genomic RNA. Virology 198:336-340
Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ (1998) Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 72:811-816
Klimatcheva E, Resenblatt JD, Planelles V (1999) Lentiviral vectors and gene therapy. Front Biosci 4:D482-496
Konvalinka J, Löchelt M, Zentgraf H, Flügel RM, Kräusslich HG (1995) Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol 69:7264-7268
Kouraklis G (2000) Gene therapy for cancer: from the laboratory to the patient. Dig Dis Sci 45:1045-1052
Kräusslich HG, Ochsenbauer C, Traenckner AM, Mergener K, Facke M, Gelderblom HR, Bosch V (1993) Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 192:605-617
Kupiec J, Kay A, Hayat M, Ravier R, Perks J, Galibert F (1991) Sequence analysis of the simian foamy virus type 1 genome. Gene 101:185-194
Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M, Lindemann D, von Kalle C, Rethwilm A, Williams DA, Hanenberg H (2002) Comparison of three retroviral vector systems for transduction of NOD/SCID repopulating CD34+ cord blood cells (submitted)
Lever A, Göttlinger H, Haseltine W, Sodroski J (1989) Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 63:4085-4087
Levy J (1993) Pathogenesis of human immunodeficinecy virus infection. Microbiol Rev 57:183-289
Lewis PF, Emerman M (1994) Passage through mitosis is required for oncoretro- viruses but not for the human immunodeficiency virus. J Virol 68:510-516
Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG (1986) AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen Sci- ence 232:1123-1127
Linial M (2000) Why aren't foamy viruses pathogenic? Trends Microbiol 8:284-289 Linial ML, Miller AD (1990) Retroviral RNA packaging: sequence requirements and implications. Curr Topics Micro Immunol 157:125-185
Löchelt M, Flügel RM, Aboud M (1994) The human foamy virus internal promoter directs the expression of the functional Bel 1 and Bet protein early after infection. J Virol 68:638-645
Löchelt M, Muranyi W, Flügel RM (1993) Human foamy virus genome posses an internal, Bel-1-dependent and functional promoter. Proc Natl Acad Sci USA 90:7317-7321
Löchelt M, Zentgraf H, Flügel RM (1991) Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel 1 gene. Virology 184:43-54
Mann R, Mulligan RC, Baltimore D (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159
Maurer B, Bannert H, Darai G, Flügel RM (1988) Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretro- virus. J Virol 62:1590-1597
McCann EM, Lever AM (1997) Location of cis-acting signals important for RNA encapsidation in the leader sequence of human immunodeficiency virus type 2. J Virol 71:4133-4137
Meiering CD, Comstock KE, Linial ML (2000) Multiple integrations of human foamy virus in persistently infected human erythroleukemia cells. J Virol 74:1718-1726
Mergia A (1994) Simian foamy virus type 1 contains a second promoter located at the 3' end of the env gene. Virology 199:219-222
Mergia A, Chari S, Kolson DL, Goodenow MM, Ciccarone T (2001) The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology 280:243-252
Mergia A, Leung NJ, Blackwell J (1996) Cell tropism of the simian foamy virus type 1 (SFV-1). J Med Primatol 25:2-7
Mergia A, Luciw PA (1991) Replication and regulation of primate foamy viruses. Virology 184:475-482
Mergia A, Pratt-Lowe E, Shaw KE, Renshaw-Gegg LW, Luciw PA (1992) cis-Acting regulatory regions in the long terminal repeat of simian foamy virus type 1. J Virol 66:251-257
Mergia A, Shaw KE, Pratt-Lowe E, Barry PA, Luciw PA (1991) Identification of the simian foamy virus transcriptional transactivator gene (taf). J Virol 65:2903-2909
Mergia A, Wu M (1998) Characterization of provirus clones of simian foamy virus type 1 (SFV-1). J Virol 72:817-822
Miele G, Mouland A, Harrison GP, Cohen E, Lever AM (1996) The human immunodeficiency virus type 1 5“ packaging signal structure affects translation but does not function as an internal ribosome entry site structure. J Virol 70:944-951
Mikovits JA, Hoffman PM, Rethwilm A, Ruscetti FW (1996) In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus. J Virol 70:2774-2780
Miller AD (1992) Human gene therapy comes of age. Nature 357:455-460
Miller AD, Buttimore C (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895-2902
Miller DG, Adam MA, Miller AD (1990) Gene transfer by retroviral vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239-4242
Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, Bock M, McClure MO, Rethwilm A (1997) Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 71:7305-11
Morgan RA, Blaese RM (1999) Gene therapy: lessons learnt from the past decade. BMJ 319:1310-12
Mountain A (2000) Gene therapy: the first decade. Trends Biotechnol 18:119-128
Muranyi W, Flügel RM (1991) Analysis of splicing patterns of human spumaretro- virus by polymerase chain reaction reveals complex RNA structures. J Virol 65:727-735
Naldini L, Blomer U, Gage FH, Trono D, Verma IM (1996a) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93:11382-11388
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996b) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267
Naviaux RK, Costanzi E, Haas M, Verma IM (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70:5701-5705
Nestler U, Heinkelein M, Lucke M, Meixensberger J, Scheurlen W, Kretschmer A, Rethwilm A (1997) Foamy virus vectors for suicide gene therapy. Gene Ther 4:1270-1277
Neumann-Haefelin D, Schweizer M, Corsten B, Matz B (1986) Detection and characterization of infectious DNA intermediates of a primate foamy virus. J Gen Virol 67:1993-1999
Paillart JC, Berthoux L, Ottmann M, Darlix JL, Marquet R, Ehresmann B, Ehresmann C (1996) A dual role of the putative RNA dimerization initiation site of human immunodeficiency virus type 1 in genomic RNA packaging and proviral DNA synthesis. J Virol 70:8348-8354
Park J, Mergia A (2000) Mutational analysis of the 5' leader region of simian foamy virus type 1. Virology 274:203-212
Park J, Nadeau PE, Mergia A (2002) A minimal genome simian foamy virus type 1 (SFV-1) vector system with efficient gene transfer. Virology 302: 236-244
Poeschla EM, Wong-Staal F, Looney DJ (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4:354-357
Renne R, Mergia A, Renshaw-Gegg LW, Neumanm-Haefelin D, Luciw PA (1993) Regulatory elements in the long terminal repeat (LTR) of simian foamy virus type 3. Virol 192:365-369
Renshaw RW, Casey JW (1994a) Analysis of the 5 ' long terminal repeat of bovine syncytial virus. Gene 141:221-224
Renshaw RW, Casey JW (1994b) Transcriptional mapping of the 3' end of the bovine syncytial virus genome. J Virol 68:1021-1028
Rethwilm A, Baunach G, Netzer K-O, Maurer B, Borisch B, ter Maulen V (1990) In- fectious DNA of the human spumaretrovirus. Nucleic Acids Res 18:733-738
Rethwilm A, Erlwein O, Baunach G, Maurer B, ter Meulen V (1991) The transcrip- tional transactivator of human foamy virus maps to the bel 1 genomic region. Proc Natl Acad Sci USA 88:941-945
Robbins P, Tahara H, Ghivizzani S (1998) Viral vectors for gene therapy. Trends Biotechnol 16:35-40
Rochlitz CF (2001) Gene therapy of cancer. Schweiz Med Wochenschr 131:4-9
Roe T, Reynolds TC, Yu G, Brown PO (1993) Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12:2099-2108
Romano G, Micheli P, Pacilio C, Giordano A (2000) Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18:19-39
Russell DW, Miller AD (1996) Foamy virus vectors. J Virol 70:217-22
Russell RA, Zeng Y, Erlwein O, Cullen BR, McClure MO (2001) The R region found in the human foamy virus long terminal repeat is critical for both Gag and Pol protein expression. J Virol 75:6817-6824
Saib A, Koken MH, van der Spek P, Perks J, de The H (1995) Involvement of a spliced and defective human foamy virus in the establishment of chronic infection. J Virol 69:5261-5268
Saib A, Puvion-Dutilleul F, Schmid M, Perks J, de The H (1997) Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 71:1155-61
Sandstrom PA, Phan KO, Switzer WM, Fredeking T, Chapman L, Heneine W, Folks TM (2000) Simian foamy virus infection among zoo keepers. Lancet 355:551-552
Schenk T, Enssle J, Fischer N, Rethwilm A (1999) Replication of a foamy virus mu- tant with a constitutively active U3 promoter and deleted accessory genes. J Gen Virol 80:1591-1598
Schmidt M, Niewiesk S, Heeney J, Aguzzi A, Rethwilm A (1997) Mouse model to study the replication of primate foamy viruses. J Gen Virol 78:1929-1933
Schmidt M, Rethwilm A (1995) Replicating foamy virus-based vectors directing high level expression of foreign genes. Virology 210:167-178
Schnell T, Foley P, Wirth M, Munch J, Uberla K (2000) Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11:439-447
Schweizer M, Falcone V, Gange J, Turek R, Neumann-Haefelin D (1997) Simian foamy virus isolated from an accidentally infected human individual. J Virol 71:4821-4824
Schweizer M, Turek R, Hahn H, Schliephake A, Netzer KO, Eder G, Reinhardt M, Rethwilm A, Neumann-Haefelin D (1995) Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retroviruses 11:161-170
Smith A (1999) Gene Therapy-where are we? Lancet 354:1-4
Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA (1986) Role of the HTLV- III/LAV envelope in syncytium formation and cytopathicity. Nature 322:470-474
Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23:628-633
Springett GM, Moen RC, Anderson S, Blaese RM, Anderson WF (1989) Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol 63:3865-3869
Tobaly-Tapiero J, Bittoun P, Neves M, Guillemin MC, Lecellier CH, Puvion-Dutilleul F, Gicquel B, Zientara S, Giron ML, de The H, Saib A (2000) Isolation and characterization of an equine foamy virus. J Virol 74:4064-4073
Tobaly-Tapiero J, Kupiec J-J, Santillana-Hayat M, Canivet M, Peries J, Emanoil-Ravier R (1991) Further characterization of the gapped DNA intermediates of human spumavirus: evidence for a dual initiation of plus-stranded DNA synthesis. J Gen Virol 72:605-608
Trobridge GD, Russel DW (1998) Helper-free foamy virus vectors. Hum Gene Ther 9:2517-2525
Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW (2002a) Improved foamy virus vectors with minimal viral sequences. Mol Ther 6:321-328
Trobridge G, Vassilopoulos G, Josephson N, Russell DW (2002b) Gene transfer with foamy virus vectors. Methods Enzymol 346:628-648
Varmus H (1988) Retroviruses. Science 240:1427-1435
Vassilopoulos G, Trobridge G, Josephson NC, Russell DW (2001) Gene transfer into murine hematopoietic stem cells with helper free foamy virus vectors. Blood 98:604-609
Venkatesh LK, Theodorakis PA, Chinnadurai G (1991) Distinct cis-acting regions in the U3 regulate trans-activation of the human spumaretrovirus long terminal repeat by the viral bell gene product. Nucl Acids Res 19:3661-3666
von-Laer D, Neumann-Haefelin D, Heeney J, Schweizer M (1996) Lymphocytes are the major reservoir for foamy viruses in peripheral blood. Virology 221:240-244
Weiss RA (1988) Foamy retroviruses. A virus in search of a disease. Nature 333:497-8
Winkler I, Bodem J, Haas L, Zemba M, Delius H, Flower R, Flügel RM, Löchelt M (1997) Characterization of the genome of feline foamy virus and its proteins shows distinct features different from those of primate spumaviruses. J Virol 71:6727-6741
Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC (1999) Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 159:34-36
Wu M, Chan S, Yanchis T, Mergia A (1998) Cis-acting sequences required for simian foamy virus type 1 (SFV-1) vectors. J Virol 72:3451-3454
Wu M, Mergia A (1999) Packaging cell lines for simian foam virus type 1 (SFV-1) vectors. J Virol 73:4498-4501
Wu N, Ataai M (2000) Production of viral vectors for Gene Ther applications. Curr Opin Biotech 11:205-208
Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43:99-112
Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T (1994) A general method for the generation of high-titer, pantropic retroviral vectors• highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 91:9564-9568
Yu H, Rabson AB, Kaul M, Ron Y, Dougherty JP (1996) Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 70:4530-4537
Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, Linial ML (1996) Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science 271:1579-1582
Yu SF, Linial ML (1993) Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol 67:6618-6624
Yu SF, Sullivan MD, Linial ML (1999) Evidence that the human foamy virus genome is DNA. J Virol 73:1565-1572
Zennou V, Petit C, Guetard D, Nehrbass U, Montgnier L, Chameau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173-185
Zucali JR, Ciccarone T, Kelley V, Johnson CM, Mergia A (2002) Transduction of umbilical cord blood CD34+ NOD/SCID repopulating cells by simian foamy virus type 1 (SFV-1) vector. Virology 302:229-235
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mergia, A., Heinkelein, M. (2003). Foamy Virus Vectors. In: Rethwilm, A. (eds) Foamy Viruses. Current Topics in Microbiology and Immunology, vol 277. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55701-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-55701-9_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62934-1
Online ISBN: 978-3-642-55701-9
eBook Packages: Springer Book Archive